CoChat

Identification of targets for rational pharmacological therapy in childhood craniopharyngioma

Open access
Gump, Jacob M., Donson, Andrew M., Birks, Diane K., Amani, Vladimir M., Rao, Karun K., Griesinger, Andrea M., Kleinschmidt-DeMasters, B. K., Johnston, James M., Anderson, Richard C. E., Rosenfeld, Amy, Handler, Michael, Gore, Lia, Foreman, Nicholas, Hankinson, Todd C. · 2015 · Acta Neuropathologica Communications
Cited by 121

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Pediatric adamantinomatous craniopharyngioma (ACP) is a histologically benign but clinically aggressive brain tumor that arises from the sellar/suprasellar region. Despite a high survival rate with current surgical and radiation therapy (75-95 % at 10 years), ACP is associated with debilitating visual, endocrine, neurocognitive and psychological morbidity, resulting in excheptionally poor quality of life for survivors. Identification of an effective pharmacological therapy could drastically decrease morbidity and improve long term outcomes for children with ACP. RESULTS: Using mRNA microarray gene expression analysis of 15 ACP patient samples, we have found several pharmaceutical targets that are significantly and consistently overexpressed in our panel of ACP relative to other pediatric brain tumors, pituitary tumors, normal pituitary and normal brain tissue. Among the most highly expressed are several targets of the kinase inhibitor dasatinib - LCK, EPHA2 and SRC; EGFR pathway targets - AREG, EGFR and ERBB3; and other potentially actionable cancer targets - SHH, MMP9 and MMP12. We confirm by western blot that a subset of these targets is highly expressed in ACP primary tumor samples. CONCLUSIONS: We report here the first published transcriptome for ACP and the identification of targets for rational therapy. Experimental drugs targeting each of these gene products are currently being tested clinically and pre-clinically for the treatment of other tumor types. This study provides a rationale for further pre-clinical and clinical studies of novel pharmacological treatments for ACP. Development of mouse and cell culture models for ACP will further enable the translation of these targets from the lab to the clinic, potentially ushering in a new era in the treatment of ACP.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40478-015-0211-5

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 121

Metadata

Authors
Gump, J. M., Donson, A. M., Birks, D. K., Amani, V. M., Rao, K. K., Griesinger, A. M., Kleinschmidt-DeMasters, B. K., Johnston, J. M., Anderson, R. C. E., Rosenfeld, A., Handler, M., Gore, L., Foreman, N., & Hankinson, T. C.
Venue
Acta Neuropathologica Communications
Published
2015-05-21
Volume
3
Issue
1
Pages
30-30
ISSN
2051-5960 (ISSN-L)
OpenAlex
W2119140098
Cited by
121
References
3
FWCI
8.61
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of targets for rational pharmacological therapy in childhood craniopharyngioma. https://app.cochat.ai/papers/10.1186/s40478-015-0211-5
The paper
Gump, J. M., Donson, A. M., Birks, D. K., Amani, V. M., Rao, K. K., Griesinger, A. M., Kleinschmidt-DeMasters, B. K., Johnston, J. M., Anderson, R. C. E., Rosenfeld, A., Handler, M., Gore, L., Foreman, N., & Hankinson, T. C. (2015). Identification of targets for rational pharmacological therapy in childhood craniopharyngioma. Acta Neuropathologica Communications. https://doi.org/10.1186/s40478-015-0211-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.